

# Pathum Weerawarna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7113447/publications.pdf>

Version: 2024-02-01

16  
papers

448  
citations

933264

10  
h-index

940416

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Theoretical and Mechanistic Validation of Global Kinetic Parameters of the Inactivation of GABA Aminotransferase by OV329 and CPP-115. <i>ACS Chemical Biology</i> , 2021, 16, 615-630.	1.6	6
2	Remarkable and Unexpected Mechanism for ( <i>S</i> )-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase. <i>Journal of the American Chemical Society</i> , 2021, 143, 8193-8207.	6.6	7
3	A Remarkable Difference That One Fluorine Atom Confers on the Mechanisms of Inactivation of Human Ornithine Aminotransferase by Two Cyclohexene Analogues of $l^3$ -Aminobutyric Acid. <i>Journal of the American Chemical Society</i> , 2020, 142, 4892-4903.	6.6	20
4	Mechanism-Based Design of 3-Amino-4-Halocyclopentenecarboxylic Acids as Inactivators of GABA Aminotransferase. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1949-1955.	1.3	6
5	Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease. <i>Proteins: Structure, Function and Bioinformatics</i> , 2019, 87, 579-587.	1.5	7
6	Design and Mechanism of ( <i>S</i> )-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent $l^3$ -Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction. <i>Journal of the American Chemical Society</i> , 2018, 140, 2151-2164.	6.6	53
7	Structure-based exploration and exploitation of the S4 subsite of norovirus 3CL protease in the design of potent and permeable inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 502-516.	2.6	20
8	Structure-based design and synthesis of triazole-based macrocyclic inhibitors of norovirus protease: Structural, biochemical, spectroscopic, and antiviral studies. <i>European Journal of Medicinal Chemistry</i> , 2016, 119, 300-318.	2.6	30
9	Potent inhibition of enterovirus D68 and human rhinoviruses by dipeptidyl aldehydes and $l^{\pm}$ -ketoamides. <i>Antiviral Research</i> , 2016, 125, 84-91.	1.9	25
10	Anti-norovirus therapeutics: a patent review (2010-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 297-308.	2.4	9
11	Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1899-1913.	2.9	24
12	Structure-Guided Design and Optimization of Dipeptidyl Inhibitors of Norovirus 3CL Protease. Structure-Activity Relationships and Biochemical, X-ray Crystallographic, Cell-Based, and In Vivo Studies. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3144-3155.	2.9	51
13	Antifungal drug discovery: the process and outcomes. <i>Future Microbiology</i> , 2014, 9, 791-805.	1.0	92
14	Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3709-3712.	1.0	40
15	Potent inhibition of norovirus 3CL protease by peptidyl $l^{\pm}$ -ketoamides and $l^{\pm}$ -ketoheterocycles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4820-4826.	1.0	54
16	In Vitro Antibacterial Activity of 4-Phenyl-1-(2-phenyl-allyl)pyridinium bromide: A Novel Class of Pyridinium Based Antibacterial Compounds. <i>Indian Journal of Microbiology</i> , 2012, 52, 83-87.	1.5	4